MiMedx Group/$MDXG
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About MiMedx Group
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
- Ticker
- $MDXG
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 808
- Headquarters
- Marietta, United States
- Website
- www.mimedx.com
MiMedx Group Metrics
BasicAdvanced
$566M
-
-$0.13
1.17
-
Price and volume
Market cap
$566M
Beta
1.17
52-week high
$7.97
52-week low
$3.03
Average daily volume
1.4M
Financial strength
Current ratio
4.351
Quick ratio
3.673
Interest coverage (TTM)
-17.93%
Profitability
EBITDA (TTM)
-17.307
Gross margin (TTM)
77.29%
Net profit margin (TTM)
-6.32%
Operating margin (TTM)
-8.28%
Effective tax rate (TTM)
14.24%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-5.38%
Return on equity (TTM)
-8.53%
Valuation
Price to revenue (TTM)
1.885
Price to book
2.68
Price to tangible book (TTM)
3.14
Price to free cash flow (TTM)
30.094
Free cash flow yield (TTM)
3.32%
Free cash flow per share (TTM)
0.129
Growth
Revenue change (TTM)
-22.80%
Earnings per share change (TTM)
-148.16%
3-year revenue growth (CAGR)
-0.57%
10-year revenue growth (CAGR)
2.96%
3-year earnings per share growth (CAGR)
73.75%
10-year earnings per share growth (CAGR)
-3.25%
What the Analysts think about MiMedx Group
Analyst ratings (Buy, Hold, Sell) for MiMedx Group stock.
Analyst projections of the future price of MiMedx Group stock.
Bulls say / Bears say
The Surgical franchise is becoming a stronger growth engine: Q3 sales rose 9% year on year, with volume up in the mid-teens, and it now makes up roughly two-thirds of revenue. Continued uptake across its product range could help offset weakness in Wound. (The Motley Fool)
Cost cuts are beginning to show through: MiMedx returned to positive adjusted EBITDA of $2 million in Q3, gross margin improved to 80% from 69% in Q2, and it finished the quarter with $121 million in cash and no debt. That gives it more room to manage the business through the reset. (MIMEDX Group, Inc.)
There are early signs that Wound demand is stabilising in specialist settings: Wound Care Centre volume grew more than 20% year on year and 7% sequentially in Q3 as patients shifted to those sites. If that migration continues, it could support a recovery despite lower reimbursement. (The Motley Fool)
The reimbursement reset has sharply reduced sales: Q3 revenue fell 45% year on year, with Wound sales down 71%, and MiMedx cut its 2026 sales outlook to $250–260 million. Surgical growth has not yet been enough to offset the decline. (MIMEDX Group, Inc.)
The Wound recovery may take longer than hoped: management said the market reset was progressing more slowly than expected, while the proposed 2027 Medicare fee schedule included no meaningful change for skin substitutes. That leaves pricing and volumes exposed beyond this year. (The Motley Fool)
The planned Sanara acquisition faces execution and financing risk: an FTC second request has extended the review, and the proposed deal relies in part on a $300 million secured loan initially priced at term SOFR plus 6.25%. A delayed or completed deal could bring added costs, leverage and integration demands. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
MiMedx Group Financial Performance
Revenues and expenses
MiMedx Group Earnings Performance
Company profitability
Upcoming events
No upcoming events
MiMedx Group News
AllArticlesVideos
What MiMedx Group (MDXG) Said on Its Q3 Earnings Call
MarketBeat4 days ago
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
Business Wire2 months ago
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
Business Wire3 months ago
Funds containing MiMedx Group
Fund name | Fund size | $MDXG weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.04% |
iShares Ageing Population£AGES | $953M | 0.04% |
iShares Ageing Population€AGED | $903M | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.